Different CARs determine what
types of tumors T cells target.
Not exact matches
By comparing the results to cells from paired normal tissue, researchers get a detailed molecular picture
of the
tumor environment, including the
types and activity levels
of T cells that are critical to the immunotherapy response.
Since the cancer cells in both
types of tumors were the same, the researchers compared the noncancerous cells present in the induced and transplanted
tumors to explore what might be causing the
T cell apoptosis.
One advantage
of this method is that it only activates a certain
type of immune cell, the dendritic cell or
T - cell, and only in one part
of the body, near the draining lymph nodes or
tumor, which helps cut down on the system - wide side effects often seen with chemotherapy.
OX40 functions as a throttle for
T cells, another
type of immune cell crucial for battling
tumors, and the anti-OX40 antibodies rev up these cells.
«Not only did we find that LIGHT expression promoted
tumor regression, upon further study we also identified the specific
type of T - cell — CD8 — that was responsible for shrinking the
tumor,» Maker said.
Tumors are home to diverse immune cell
types, some
of which remain much less explored than
T cells and could also control cancer progression» says Mikael Pittet, PhD, director
of the Cancer Immunology Program in the MGH Center for Systems Biology and senior author
of the Science paper.
Genetically modified «hunter»
T cells successfully migrated to and penetrated a deadly
type of brain
tumor known as glioblastoma (GBM) in a clinical trial
of the new therapy, but the cells triggered an immunosuppressive
tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat this aggressive cancer, Penn Medicine researchers report in a new study this week in Science Translational Medicine.
The research, published online May 26 by Nature Immunology, shows that GATA - 3 is required for the maintenance and function
of CD8 +
T - cells, a
T - cell
type mediating the immune response to clear pathogens, eradicate
tumors and promote inflammation.
We believe that each dog breed may correspond to one
type of B - or
T - cell lymphoma and so studies within and between breeds gives us a unique possibility to understand how the genetic background affects what
type of tumor develops, and how its progression is regulated,» says Ingegerd Elvers.
Results
of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression
of both treated and untreated
tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous
T cell lymphoma (CTCL)-- a rare
type of non-Hodgkin lymphoma that affects the skin.
Cells
of the latter cancer
types contain many DNA mutations, which are thought to make distinctive «neoantigens» that help the patient's immune system recognize and attack
tumors, and make the cancer cells» «microenvironment» hospitable to
tumor - fighting
T cells.
«The apparent ability to change immunosuppressive
T cells within the
tumor into
T cell
types that are more active and potentially helpful against cancer was a really exciting finding, and one that we're continuing to investigate,» says Poznansky, who is an associate professor
of Medicine at Harvard Medical School (HMS).
Immunity is key to long - term responses Knowing that the immune system is capable
of recognizing distinctive features
of cancer cells and launching a
T cell attack against those
tumor antigens, and that checkpoint blockade removes a roadblock to that attack, it's logical that these drugs should work against many
tumor types.
While the study focused on the
T - cells around a lymphoma
tumor, this research is pertinent to all
types of cancer.
Scientists have known that LPA is secreted by many
types of cancer cells, appears to promote the growth and spread
of tumor cells, and that immune cells known as CD - 8 «killer»
T cells have several receptors for LPA.
Interestingly, p21 - deficient mice did not develop
T - cell lymphomas, which is one
of the most common
tumor types in p53 - null mice (36, 37, 38).
Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic
T - cell response against different
types of tumors.
It is interesting to note that p21 - deficient mice did not develop
T - cell lymphomas, which is one
of the most common
tumor types in p53 - null and p19ARF - null mice (36, 37, 38, 42, 43).
So, the researchers forced expression
of a dominant - negative TGF - β receptor
type 2 (DNRII) onto LMP - specific
T cells (DNRII - LSTs) that were specially designed to seek out and destroy proteins derived from the Epstein - Barr virus expressed by the
tumor cells.
To get there, researchers will need to resolve certain obstacles associated with CAR -
T, including further customization
of the technology to recognize specific / other
tumor types, and predicting and limiting cross-reactivity, where CAR -
T immune cells start attacking healthy cells as well.
In cancer, Tregs are recruited by
tumors and prevent other
types of T cells, including cytotoxic
T cells (also called CD8 cells) from attacking and destroying cancer cells.
For example, new data has shown that
tumors that are infiltrated by
T cells — a
type of white blood cell that plays an important role in immunity — translate to better outcomes in response to immunotherapy.
T - VEC, recently approved for the treatment
of advanced melanoma, is an oncolytic herpes simplex virus
type 1 engineered to replicate selectively in
tumor cells and express human granulocyte - macrophage colony - stimulating factor.
The numerous flavonoids found in astragalus appear to enhance cell - mediated immunity by increasing the number
of T - helper cell
type 2 cytokines, increasing levels
of tumor necrosis factor and interleukin - 6, which stimulates the activity
of macrophages, responsible for killing potentially harmful cells.
The
tumors in the active mice contained more
of two
types of cancer - killing cells, explains Quartz, «double the number
of T - cells and five times the number
of natural killer cells.»